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An atypical role for the myeloid receptor
Mincle in central nervous system injury
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Abstract
The C-type lectin Mincle is implicated in innate immune responses to sterile inflammation, but its contribution to
associated pathologies is not well understood. Herein, we show that Mincle exacerbates neuronal loss following ischemic
but not traumatic spinal cord injury. Loss of Mincle was beneficial in a model of transient middle cerebral artery occlusion
but did not alter outcomes following heart or gut ischemia. High functional scores in Mincle KO animals using the focal
cerebral ischemia model were accompanied by reduced lesion size, fewer infiltrating leukocytes and less neutrophil-
derived cytokine production than isogenic controls. Bone marrow chimera experiments revealed that the presence of
Mincle in the central nervous system, rather than recruited immune cells, was the critical regulator of a poor outcome
following transient middle cerebral artery occlusion. There was no evidence for a direct role for Mincle in microglia or
neural activation, but expression in a subset of macrophages resident in the perivascular niche provided new clues on
Mincle’s role in ischemic stroke.
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Introduction
Ischemic stroke results in the loss of neurons in the
perfusion territory of the aﬀected blood vessel via neu-
rodegenerative mechanisms and concomitant inﬁltra-
tion of activated leukocytes.1 Chronic inﬂammatory
conditions or infection increase the risk of stroke, and
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worsen outcome.2,3 Molecular models of innate
immune signaling show that inﬂammatory modulation
can confound outcomes in stroke. For example, block-
ing the toll-like receptor (TLR), immune receptor
family limits tissue damage.4,5 However, targeting
immune signaling via MyD88 provided no beneﬁt for
neurological outcomes, but worsened neuronal cell
death in animals subjected to global or focal ische-
mia.6,7 In mouse models of spinal cord injury (SCI),
blocking Tlr2 or Tlr4 reduced microglia activation8
but worsened tissue damage and recovery.9 The pres-
ence of TLRs in the central nervous system (CNS) is
suggested to be neuroprotective, whereas increased
expression of TLR2 and 4 in peripheral leukocytes
is concordant with higher inﬂammatory markers in
clinical stroke and is predictive of poor outcome in
stroke patients.10
High circulating neutrophil numbers are positive pre-
dictors of stroke severity.11 Strategies that reduce neu-
trophil inﬂux to the site of ischemic injury reduce
inﬂammation, collateral blood vessel occlusion and the
severity of injury.12–14 However, blocking the phagocytic
clearance of dead cells by microglia will exacerbate
injury,15 and reparative roles of tissue macrophages are
necessary for wound healing and functional recovery
from sterile inﬂammation.16 This suggests that func-
tional diﬀerences in inﬁltrating or resident myeloid
cells during the acute phase of sterile injury are import-
ant determinants of recovery from stroke.
Mincle (Clec4e) is a myeloid receptor that has been
reported to recognize necrotic cells via detection of the
nuclear protein Sap130.17 Mincle regulates inﬂamma-
tory responses to fungal and mycobacterial patho-
gens18–21 via spleen tyrosine kinase (Syk), and the
caspase recruitment domain protein Card9.22,23
Inhibition of Syk limits thrombosis and vascular
inﬂammation in a variety of animal models of sterile
injury;24 therefore, the Mincle/Syk axis is likely to also
contribute to the pathophysiology of ischemic stroke.
Two previous studies used Syk inhibition to suggest
a deleterious role for Mincle in subarachnoid haemor-
rhage25 and ischemic stroke,26 but as Syk is not select-
ive, the role of Mincle in stroke remains poorly deﬁned.
In the current study, we used the Clec4e/ mouse,
together with bone marrow chimeras, to demonstrate
an atypical role for Mincle in ischemic stroke outcomes.
Using the KO mouse to determine antibody speciﬁcity,
we demonstrate that Mincle does not have the wide-
spread brain expression previously described,25,26 but
instead is restricted to perivascular macrophages and
peripheral leukocytes. Absence of Mincle did not
aﬀect outcomes following traumatic SCI, or of ischemic
injuries in other organs, such as the heart or the intes-
tine. The combined data presented here suggest a key
role for Mincle in ischemic CNS injuries, where the
integrity of the blood–brain/spinal cord barrier is not
compromised by mechanical forces during the initiating
event.
Materials and methods
Animals
All experimental procedures followed the ‘‘Australian
code of practice for the care and use of animals for
scientiﬁc purposes,’’ approved by The University of
Queensland and Monash University Animal Ethics
Committees (ethics license numbers SBMS/358/12/
NHMRC/ARC, SBMS/085/09, MARP-2011-175 and
SBMS/311/12/SPINALCURE), and further husbandry
details, including ARRIVE guidelines for reporting
animal research are available in the supplementary
methods.
Homozygous null C57Bl/6J Clec4e/ mice were
used as previously described,21 and they were compared
to a control cohort of isogenic C57BL/6J or cohoused
Clec4eþ/ littermates, which exhibited equivalent
immune phenotypes in this and previous studies.27
Full details on animal numbers assigned to each experi-
ment are described in the supplementary methods.
Unless otherwise stated, a randomized experimental
designed was used, where littermates (Clec4eþ/ or
Clec4e/) were cohoused and animals were selected
at random by an operator who was blind to the geno-
type of the animals and the analysis of material was
conducted in a double-blinded manner.
Focal cerebral ischemia model
Male, three to six-month-old mice were anesthetized for
focal cerebral ischemia by transient middle cerebral
artery occlusion (tMCAO). The ﬁrst round of surgery
(Figures 1 and 2) did not use a randomized experimen-
tal design. For all other tMCAO, including bone
marrow chimeras (Figure 3, n¼ 70), and microglia pro-
ﬁling (Figure 5, n¼ 16), operators were blinded to
genotype or treatment group and randomization was
based on predesigned lists using color-coded cages
and reagents. Exclusion criteria were excessive bleeding
or death within 24 h after tMCAO. Details of the
tMCAO surgery have been published previously4,5
and are provided in the supplementary methods.
Animals were subjected to cerebral blood ﬂow measure-
ments using a laser Doppler perfusion monitor (Moor
Lab) placed perpendicular to the surface of the right
parietal skull (1mm posterior and 5mm lateral to the
bregma) to monitor blood ﬂow in the MCAO territory.
Syk inhibitor BAY61-3606 (B9685, Sigma-Aldrich)
was injected (femoral vein), 1mg/kg (25 ll) 30min
before tMCAO, or 3 h post-reperfusion.
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Quantification of cerebral infarction and neurological
deficit assessment
Infarct areas were calculated at three or seven days
post-reperfusion from digitized sections stained with
2% 2,3,5-triphenyltetrazolium chloride (TTC, T8877
Sigma-Aldrich) using NIH image 6.1 software. To cor-
rect for brain swelling, the infarct area was determined
by subtracting the area of undamaged tissue in the
left (ipsilateral) hemisphere from that of the whole
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Figure 1. Mincle signaling worsens brain damage and functional outcome after transient MCAO. Mice of the indicated genotypes
were subjected to sham surgery or transient middle cerebral artery occlusion (tMCAO), and brain damage and neurological function
were evaluated (a) Representative TTC-stained brain sections from WT and Clec4e/ mice three days post-reperfusion. Infarct
volumes (b) for WT mice subjected to sham surgery (n¼ 6), and WT (n¼ 27) and Clec4e/ (n¼ 14) mice three days after tMCAO.
Bars represent mean. (c) The corresponding daily neurological deficit scores are shown as median and range. (d) Infarct volumes for
WT (n¼ 8) and Clec4e/ (n¼ 8) mice seven days after tMCAO are significantly different as shown by t-test. (e) The corresponding
daily neurological deficit scores are shown as grouped with median and range. (f) Laser Doppler flowmetry shows no differences
between samples in the extent to which MCAO compromises blood flow. (g) TUNEL-positive cells were quantified in both
hippocampus and cortex from control (n¼ 4), WT (n¼ 6) and Clec4e/ (n¼ 6) mice after global cerebral ischemia. The percentage
of TUNEL-positive cells is represented showing median, the 25th to 75th percentiles, and min-max range. (h) Representative
TTC-stained brain sections from mice treated with vehicle or the Syk inhibitor BAY-61-3606, three days post-reperfusion. (i) Infarct
volumes for WT mice subjected to sham surgery (n¼ 6), vehicle-treated (n¼ 11) mice, or mice treated with BAY-61-3606 before
MCAO (n¼ 9) or 3 h after the onset of reperfusion (n¼ 10), three days after tMCAO. (j) The corresponding daily neurological deficit
scores are as median and range, and both pre- and post-treated samples are significantly different from vehicle control. Tests: (b, i, g)
ANOVA, (c, j) Kruskal–Wallis, (d) t-test, (e) Mann–Whitney. ***: p< 0.001, **: p< 0.01, *: p< 0.05, ns: not significant; comparisons
indicated by brackets. Scale bar for images: 1mm.
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contralateral hemisphere. Infarct volume was calcu-
lated by integration of infarct areas for all slices of
each brain, and then expressed as a % of the ipsilateral
hemisphere. The functional consequences of tMCAO
were evaluated using a 5-point neurological deﬁcit
score (0, no deﬁcit; 1, failure to extend right paw;
2, circling to the right; 3, falling to the right; and
4, unable to walk spontaneously28).
Global ischemia model and TUNEL assay
Adult male, age-matched C57BL6/J WT (n¼ 4) and
Clec4e/mice (n¼ 6) were used. Transient global cere-
bral ischemia was performed by the two-vessel
occlusion model1 and described in more detail
in the supplementary methods. The In Situ Cell
Death Detection Kit, POD (11684817910, Roche,
Switzerland) was used according to manufacturer’s
instructions, and tissue was counterstained with Gills
hematoxylin. Sections treated with 100 U/ml recombin-
ant DNase I were used as positive control.
Flow cytometry
Protocols for ﬁxation and perfusion of brains after
tMCAO have been previously described,29 and details
provided in the supplementary methods. In brief, each
experiment consisted of a pool of three lesioned or ipsi-
lateral hemispheres. Cellular fractions were isolated
from collagenase digested tissue, separated from
myelin and debris, then incubated appropriate antibo-
dies (see supplementary methods). Data were acquired
with a LSR II FACS system (BD Biosciences) and ana-
lyzed with FlowJo (TreeStar). Doublets were excluded
with FSC-A and FSC-H linearity.
Generation of bone marrow chimeric mice
Recipient mice (three to six months of age) were sub-
lethally irradiated with 2 5 Gy, 14 h apart. Immune
system rescue via bone marrow transplantation from
either WT or Clec4e/ donors, 3–4 h after the second
dose of irradiation. Chimeric mice recovered> 3
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Figure 2. Neutrophil infiltration was significantly reduced in Clec4e/ mice following tMCAO. (a) Flow cytometry of leukocytes in
the ipsilateral hemisphere showed a significantly lower proportion of infiltrating neutrophils (CD45high, CD11bþ, Ly6Gþ) in Clec4e/
mice at one and three days post-reperfusion. (b) There were fewer TNF-positive infiltrating neutrophils and CD11c monocytes in
Clec4e/ compared to WT mice 24 h after reperfusion. (c) Flow cytometry revealed a significantly lower proportion of infiltrating
leukocytes (CD45high, CD11bþ) in Clec4e/ mice than in WT controls 24 h post-reperfusion. (d) No differences in the proportion of
infiltrating neutrophils or in TNF-positive leukocytes were observed. t-test: ***: p< 0.001, **: p< 0.01, ns: not significant.
Comparisons indicated by brackets. % cells in (a) and (c) are represented by box and whiskers plots, showing median, the 25th to 75th
percentiles, and min-max range. % TNF-positive cells are represented by meanþ s.e.m.
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months for full reconstitution of the peripheral immune
compartment, conﬁrmed as >95% donor engraftment
eﬃciency by relative frequency of donor and host white
blood cells, on the basis of CD45.1þ/ CD45.2þ antigen
expression. Mice were color coded prior to surgery and
subjected to tMCAO by an experimenter blinded to the
genotype or treatment groups. Infarct size was deter-
mined as detailed above.
SCI and assessment of locomotor recovery
Adult, age- and weight-matched female C57BL6/J WT
(n¼ 12) and Clec4e/mice (n¼ 14) were used for these
experiments. Order of surgery was randomized based
on predesigned lists, with the experimenter conducting
the surgery remaining blinded to genotype throughout
all aspects of surgery. A severe contusive SCI as previ-
ously described is given with full details in the supple-
mentary methods.30–32 Brieﬂy, the procedure involved a
dorsal laminectomy and a force-controlled 70 kilodyne
(kd) impact applied at spinal level T11, using the
Inﬁnite Horizon impactor device (precision systems
and instrumentation). Recovery of hind-limb function
was assessed using the 10-point Basso Mouse Scale
(BMS), a system designed speciﬁcally for the assess-
ment of murine locomotor recovery following SCI.33
Multiple aspects of locomotion, including ankle move-
ment, stepping, co-ordination, paw placement, trunk
stability and tail position were assessed using this
scale. Experimental animals were randomly picked up
from their cages and assessed by two investigators
blinded to the genotype at one, four, seven days post-
SCI and then weekly thereafter up until the study end-
point (35 days post-injury). Animals deviating>5
kdyne from the mean force, or spinal cord tissue dis-
placement 100 mm from the experimental mean were
excluded. For the remaining n¼ 10 mice per genotype,
the actual applied force and displacement for WT and
Clec4e/ animals were 75.40 0.91 vs. 74.10 0.99
kdyne (p> 0.34), and 537.7 15.22 vs.
535.9 18.11 mm, respectively (p> 0.94).
Spinal cord tissue sectioning and immunofluorescence
In brief, mice were euthanized at day 35 post-injury.
Transverse 20lm thick sections of spinal cord were
cut, processed and stained with appropriate antibodies
as described in the supplementary methods. Images were
captured on a single plane using a Zeiss Axio Imager and
Zen Blue 2012 Software (Zeiss), and analyzed with
ImageJ software. Section areas were determined by out-
lining the section boundary on the GFAPþ channel
(excluding the leptomeninges). Proportional area meas-
urements were calculated by thresholding the
FluoroMyelin Red stained area in ImageJ and dividing
it by the total section area. Lesion volumes and/or length
were calculated by multiplying ﬁbronectinþ areas by the
section thickness and 1:5 series count.
Intestinal ischemia and reperfusion, histological
analysis and myeloperoxidase quantification
Details on surgical procedures are provided in the sup-
plementary methods. Brieﬂy, the surgeries were not
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Figure 3. The origin of the Clec4e/ protective effect is in the central nervous system. (a) Ipsilateral infarct volume three days after
tMCAO from bone marrow chimeras obtained between WT (C57BL/6J mice carrying the CD45.1 allele) and Clec4e/ animals.
Donor and recipient genotypes indicated on the X-axis. Bars represent median and range. (b) Neurological deficit scores of bone
marrow chimeras, assessed daily for three days, shown as median and range, where both Clec4e/ recipient samples are significantly
different fromWT>WT sample. WT donor to WTrecipient, n¼ 18; Clec4e/ donor to WTrecipient, n¼ 17; WT donor to Clec4e/
recipient, n¼ 18; Clec4e/ donor to Clec4e/ recipient, n¼ 17. ANOVA: ***: p< 0.001, **: p< 0.01, ns: not significant. Comparisons
indicated by brackets.
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randomized, but tissues were collected into coded tubes
and the analysis performed by an operator blind to
genotype. A ligature was tied with silk suture material
around the superior mesenteric artery except in animals
undergoing sham surgery. After 30min of ischemia,
the ligature was removed, and after 2 h of reperfusion,
the mice were euthanized. For histological analysis,
three portions of small intestine were stored in 4%
paraformaldehyde for 24 h. Tissues were embedded in
paraﬃn wax, sectioned transversely and stained with
hematoxylin/eosin. The average of villi damage was
determined after grading each of 100 villi per mouse
on a 0–6 scale as previously described.34 For MPO
activity, three portions of small intestine were homoge-
nized in 50mM potassium phosphate, centrifuged
and pellets resuspended in 0.25mM hexadecyltrimethy-
lammonium bromide (H5882, Sigma-Aldrich) for
MPO solubilization. After homogenization and centri-
fugation, supernatants were assayed with 1.21mg/ml o-
dianisidine dihydrochloride (D3252, Sigma-Aldrich)
and 2.17% hydrogen peroxide, and absorbance read
at 460 nm.
Myocardial infarction and echocardiography analysis
All animals in the same cage (siblings) were experi-
mented on in a blinded fashion (for both echocardiog-
raphy and surgery). Genotypes were checked after the
experiment was ﬁnalized. To induce myocardial infarc-
tion, the left coronary artery (LDCA) of 10-week-old
mice was ligated. For non-invasive echocardiography,
in homeostasis or one month after surgical interven-
tion, mice were anaesthetized and kept sedated
under 1.5% isoﬂurane. Imaging was performed in
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Figure 4. Absence of Mincle does not affect the outcome of spinal cord injury, intestinal ischemia and reperfusion (I/R) or myo-
cardial ischemia. (a) No significant differences between genotypes (n¼ 10) in 35 days post-injury BMS locomotor scores (ANOVA;
p> 0.05), or at endpoint (b). (c) Representative GFAPþ/Fibronectinþ staining for the quantification of lesion core in WTand Clec4e/
mice. No significant differences were found between genotypes in either lesion core volume (d, t-test p> 0.05) or length (e, t-test
p> 0.05). Bars represent mean. Scale bar for images: 200 mm. Quantification of myelin staining in WT and Clec4e/ spinal cords (f)
revealed no significant differences between genotypes (g). Intestinal I/R revealed no differences between genotypes with regards to
pathology scores (h) or to levels of myeloperoxidase (MPO) an indicator of neutrophil infiltration (i). Whole mount views and
histological sections of control and mutant hearts after one month of infarction (j). Trichrome staining, representative of n¼ 10, shows
scarring (blue) and viable myocardium (red) at various transverse levels of the heart, from apex (left panel) to base (right panel). (k–o)
Echocardiography analysis of control and mutant hearts after one month of infarction (Clec4eþ/ and WT animals, n¼ 14, Clec4e/
animals, n¼ 11). (k) Representative images of infarcted hearts in systole and diastole. Ejection fraction (EF – l), end systolic volume
(ESV – m) and end diastolic volume (EDV – n), as well as other analyzed parameters, are not significantly altered in mutant hearts,
suggesting that Clec4e is not implicated in the regenerative response after myocardial infarction. Left ventricular mass (LVM – o) was
used as an indication of heart size in homeostasis and is not significantly different between control and mutant hearts.
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spontaneously breathing animals in prone position
using Vevo 2100 Imaging System (FUJIFILM
VisualSonics) equipped with 18 to 38 MHz linear
array transducer. Standard parasternal long- and
short-axis views were obtained to assess left ventricular
chamber function. Function was calculated using
Vevo2100 Cardiac Measurements Package. Mice were
euthanized one month after surgery, and their hearts
dissected for histology.
Cell culture, and oxygen and glucose deprivation
The murine brain endothelial cell line bEnd.3 (CRL-
2299) and the murine macrophage line RAW264.7
cells (TIB-71) were obtained from ATCC. Neuronal
cultures were established from littermate 16-day-old
WT, Clec4eþ/ or Clec4e/ mouse embryos, and
ascertained by immunoﬂuorescence to be 95% neurons
and 5% astrocytes. Glial cultures were established from
postnatal day 1 WT, Clec4eþ/ or Clec4e/ mice.
Microglia were separated from astrocytes with the use
of CD11b (Microglia) MicroBeads (Miltenyi Biotec).
For oxygen and glucose deprivation (OGD), cultures
were incubated with glucose-free Locke’s buﬀer (in
mmol/L: 154 NaCl, 5.6 KCl, 2.3 CaCl2, 1 MgCl2, 3.6
NaHCO3, 5 HEPES, pH7.2, supplemented with genta-
mycin 10mg/L) placed in an incubator, where the
oxygen was displaced with nitrogen to a level of
Figure 5. Mincle could not be found in microglia, neurons, astrocytes or endothelial cells. (a) An antibody that detects Mincle in the
mouse macrophage cell line RAW264.7, and shows its upregulation by LPS, does not detect Mincle in cultured microglia in basal
conditions or stimulated with LPS or oxygen and glucose deprivation (OGD). Scale bar: 10mm. (b) MIP2a qRT-PCR in Clec4eþ/ and
Clec4e/ cultured microglia from neonatal mice shows that Mincle does not contribute to MIP2a gene expression in microglia, and
Mincle sufficient microglia do not produce MIP2a in response to the Mincle-specific ligand trehalose dimycolate (TDM). Data points
represent different cultures, each derived from a single mouse (c) Ex vivo microglia upregulate Clec4e expression under OGD, as
measured by qRT-PCR. (d) WT microglia sorted from the ipsilesional brain hemisphere 24 h after tMCAO do not show Clec4e
upregulation, as shown by microarray, sham n¼ 3 per genotype, tMCAO n¼ 5 per genotype (dt: detection threshold, 3.38; med:
median, 6) (e, f) Volcano plots for differences in microglial gene expression between sham surgery and tMCAO for WT mice (e), and
between WTand Clec4e/ tMCAO (f), show that, whether there are notable differences in microglial gene expression between sham
surgery and tMCAO followed by 24 h reperfusion, Clec4e is not a contributing factor. Red dots:> 1.5 upregulated in the first sample
mentioned above graph (p< 0.05); blue dots:> 1.5 downregulated in the first sample mentioned above graph (p< 0.05). (g) Absence
of Clec4e mRNA in primary cortical neurons (left), cells of the brain endothelial cells line bEND.3 and primary astrocytes (right),
untreated or under a time course of OGD (n¼ 3). RNA from WT bone marrow-derived macrophages treated with LPS for 3 h is the
positive control for all samples (n¼ 1).
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0.2%, and incubated for 3 h. Incubation with trehalose
6,6 dimycolate (Sigma Aldrich) was conducted for 24 h.
Microglia isolation and microarray
WT and Clec4e/ mice were coded and randomized
for tMCAO surgery and FACs proﬁling as described
above, and in supplementary methods. Microglia were
isolated 24 h post tMCAO. For each proﬁled replicate,
two ipsilesional hemispheres (with cerebellum and
brainstem removed) were pooled for microglia isola-
tion. For sham-operated animals, the whole forebrain
was used and brains were not pooled. After myelin sep-
aration by Percoll gradient centrifugation, 80,000
CD45intermediate, CD11bþ microglial cells were sorted
from each sample. Doublets were excluded with FSC-
A and FSC-H linearity, and dead cells excluded using
Zombie VioletTM Fixable Viability Kit (423113,
BioLegend). RNA was isolated as described above.
Samples were ampliﬁed (GeneChip WT Pico Kit
902623, Aﬀymetrix) and processed with the Mouse
2.0ST Gene Array WT pico assay (902463,
Aﬀymetrix) by the Ramaciotti Centre for Genomics,
University of New South Wales. The expression data
(RMA background corrected, quantile normalized) are
hosted by www.stemformatics.org (dataset S4M-
6731)35 and is available from GEO (Accession
GSE77986). The expression threshold was calculated
as the median expression of all antigenomic probesets
on the microarray (log2 3.38). Probes that failed to be
expressed above detection threshold in the majority of
biological replicates in at least one comparison group
were removed from the analysis. The R/Bioconductor
limma36 package was used to ﬁnd diﬀerentially
expressed genes (DEG) at FDR p< 0.01.
Identification of Mincle-expressing cells by IF
Mouse cultured cells were ﬁxed in 4% paraformalde-
hyde; 6 lm microtome sections from Wistar Kyoto or
spontaneously hypertensive stroke-prone (SHRSP) rats
subjected to permanent MCAO for 24 h using dia-
thermy with modiﬁcation were obtained from a previ-
ous study.37 Antibodies are described in the
supplementary methods. Images were acquired using
an Olympus BX61 microscope (Japan).
qRT-PCR
RNA was isolated (RNeasy Plus Mini Kit, 74134,
Qiagen), and cDNA synthesized using iScript Reverse
Transcription Supermix, Bio-Rad. qPCR was per-
formed with FastStart Universal SYBR Green Master
[Rox] (04913850001, Roche). Primer sequences are pro-
vided in the supplemental methods.
Data analysis
Unless indicated otherwise, the experimental unit for in
vivo experiments was a single animal. For neurological
deﬁcit scores, diﬀerences between experimental condi-
tions were assessed using a Kruskal–Wallis test
followed by Dunn’s multiple comparison test, or
Mann–Whitney test. Assessment of variance between
all other experimental groups was determined by one-
way analysis of variance (ANOVA) followed by
Neuman–Keuls multiple comparisons test, or two-
tailed Student t-test as appropriate, and the speciﬁc
tests applied are indicated in all ﬁgure legends. Unless
stated, error bars show standard deviation (s.d.).
Results
Mincle deficiency improves functional outcomes
and reduces infarct size in mouse models of
cerebral ischemia
Mincle knock out mice (Clec4e/) were used to assess
the impact of Mincle on stroke-induced inﬂammation
and tissue damage following 1 h tMCAO. In all func-
tional and physiological measures, the Clec4e/ group
had fewer impairments than isogenic WT controls,
including 50% smaller infarct volume (TTC staining)
at three days post-stroke (Figure 1(a) and (b)), and
lower neurological deﬁcit scores (Figure 1(c)). These
ﬁndings were corroborated in an independent experi-
ment in mice monitored up to seven days post-stroke,
with the Clec4e/ group recording an overall and sig-
niﬁcant decrease in infarct size and neurological deﬁcit
scores compared to the WT group (Figure 1(d) and (e)).
Arterial blood ﬂow, measured by laser Doppler ﬂow-
metry during ischemia, was equivalent between the
groups (Figure 1(f)) and both genotypes showed com-
parable recovery 24 h after reperfusion. Clec4e/ mice
subjected to global cerebral ischemia had signiﬁcantly
fewer TUNEL-positive cells than the control group,
indicating loss of Mincle was associated with less apop-
tosis in hippocampus and cortex (Figure 1(g)).
Mice treated with the Syk inhibitor BAY61-3606
before tMCAO, or 3 h after reperfusion, showed
>50% decrease in infarct volume (Figure 1(h) and (i))
and greater functional scores than vehicle-treated mice
(Figure 1(j)), supporting the eﬃcacy of Syk inhibitors in
this stroke model.
Mincle and its downstream partner Syk mediate
reperfusion-induced leukocyte brain infiltration
Immune cell populations present in ipsilateral brain
hemispheres from WT and Clec4e/ mice were ana-
lyzed by ﬂow cytometry over the ﬁrst three days post-
reperfusion. The recruitment of neutrophils (CD45high,
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CD11bþ, Ly6Gþ) to the injured brain parenchyma at
one or three days after tMCAO was signiﬁcantly less in
Clec4e/ than WT mice (Figure 2(a)). Fewer TNF-
positive neutrophils, as well as fewer CD11c mono-
cytes (CD45high, CD11bþ, CD11c) were observed
one day after reperfusion in Clec4e/ than control
groups (Figure 2(b)). It is noteworthy that microglia
(CD45intermediate, CD11bþ), which appeared to be the
primary source of TNF in the injured hemisphere,
showed no diﬀerence in activation between genotypes
(Figure 2(b)). A single dose of the Syk inhibitor 3 h
after tMCAO also impacted on inﬂammatory cell
recruitment with signiﬁcantly fewer CD45high cells in
the Syk-treated animals compared to the vehicle-treated
group on day 1 (Figure 2(c)); however, no diﬀerences
were recorded between vehicle and inhibitor-treated
animals on day 3 after tMCAO. In contrast to the
lower numbers of TNFþ leukocytes recorded in
Clec4e/ mice (Figure 2(a) and (b)), no diﬀerences in
TNF-positive myeloid cells were observed between WT
animals treated with Syk inhibitor or vehicle control
(Figure 2(d)).
Ischemia-induced tissue damage is driven by Mincle
expression in the brain, not peripheral blood cells
We next aimed to determine whether Mincle inﬂuences
stroke outcomes via its expression in circulating mye-
loid cells, CNS-resident cells, or a combination thereof.
Bone marrow chimera experiments showed that a lack
of Mincle in the peripheral immune compartment
(Clec4e/ marrow to WT recipient) had a small but
signiﬁcant eﬀect on infarct volume after tMCAO
(Figure 3(a) and (b)), indicating a partial contribution
of bone marrow-derived cells to the Clec4e/ pheno-
type. Clec4e/ mice that received a WT bone marrow
transplant (WT to Clec4e/), to reinstate Mincle
expression on circulating myeloid but not CNS-resident
cells, were equally well protected against tMCAO as the
chimeric group with global Clec4e deﬁciency (Clec4e/
to Clec4e/) based on both infarct volumes and neuro-
logical deﬁcit scores (Figure 3(a) and (b)). Loss of
Mincle on CNS-resident cells thus appears to be the
critical contributor towards the protective phenotype
observed in Clec4e/ mice.
Mincle deficiency does not influence the outcome
from traumatic CNS injury or peripheral organ
ischemia
We theorized that if Mincle is a general activator in the
local response to tissue damage, then it may also play a
key role in other models of tissue injury. Lack of
Mincle did not result in an altered and/or improved
recovery from contusive SCI, with no diﬀerences
observed between genotypes for hind-limb locomotor
performance up to at least 35 days post-injury
(Figure 4(a) and (b)), nor did absence of Mincle alter
lesion volume, lesion length, or myelin preservation
(Figure 4(c) to (g)). We observed no role for Mincle
in two models of peripheral ischemic injury; intestinal
ischemia/reperfusion, or myocardial infarction. WT
and Clec4e/ mice subjected to 30min of ischemia
and 2 h of blood reperfusion showed similar gut path-
ology scores (Figure 4(h)). Neutrophil recruitment to
the injured intestine, based on myeloperoxidase
(MPO) content in the tissue, was not Mincle-dependent
(Figure 4(i)). A similar level of scarring was observed
between the hearts of Clec4e/ mice (n¼ 11), Clec4eþ/
littermates and WT animals (combined n¼ 14) at one
month following myocardial infarction (Figure 4(j)).
Echocardiography analysis of heart chamber function,
either in homeostasis or one month after surgical inter-
vention (Figure 4(k)), revealed no signiﬁcant diﬀerences
between genotypes in ejection fraction (Figure 4(l)),
or systolic and diastolic end volume (Figure 4(m)
and (n)). Left ventricular mass was also similar for
both genotypes in homeostasis (Figure 4(o)), conﬁrm-
ing a lack of size bias in baseline homeostatic functional
parameters.
Mincle expression in the brain is restricted to
a specific cell type
To better understand the unique role of Mincle in ische-
mic stroke, we performed a careful search for the cell(s)
in the CNS expressing Mincle. Given that Mincle is a
myeloid cell receptor, we ﬁrst assessed microglia.
Immunoﬂuorescence with 1B6, a rat antibody that rec-
ognizes Mincle in the mouse macrophage cell line
RAW264.7, showed no expression of Mincle in micro-
glia cultures derived from neonatal brains. Stimulation
with OGD as an in vitro model of ischemia also failed
to increase Mincle staining (Figure 5(a)). We next
determined whether microglia were functionally com-
petent to respond to the Mincle-ligand trehalose dimy-
colate (TDM), by measuring production of the target
chemokine Cxcl2 (Mip2a).19 Cultured microglia upre-
gulated Mip2a expression in response to OGD regard-
less of their genotype; however, WT (Clec4eþ/)
microglia failed to induce Mip2a mRNA in response
to TDM stimulation, indicating a lack of Mincle-
dependant signaling in these cells (Figure 5(b)).
Clec4eþ/ primary microglia did upregulate Clec4e
mRNA in response to OGD (Figure 5(c)), suggesting
the possibility that Mincle may play a role in microglia
during tMCAO. We therefore sorted microglia
(CD45intermediate, CD11bþ) by FACS from the ipsile-
sional hemispheres of Clec4e/ and WT controls,
24 h after either tMCAO or sham surgery, for
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transcriptome proﬁling. Clec4e mRNA was not higher
in WT microglia after tMCAO (Figure 5(d)). As
expected, dramatic alterations in gene expression
were observed between microglia from tMCAO mice
compared to their sham-operated counterparts
(Figure 5(e)), but the presence or absence of Mincle
itself did not aﬀect microglial gene expression
(Figure 5(f)). The observations that Mincle is not
expressed by, nor functional in, microglia thus exclude
microglia as the primary mediators of the neuroprotec-
tive phenotype in Clec4e/ mice.
Close evaluation of Mincle expression, using both
mRNA and protein analysis on WT and Clec4e/
mice, also failed to reveal Mincle expression by other
cell types such as primary neurons, the brain endothe-
lial cell line bEND.3, or primary astrocytes, including
in response to OGD (Figure 5(g)). Mincle mRNA was
also not detectable by qPCR in various human neur-
onal cell lines (CHP-212 or SH-SY5Y), nor under a
variety of metabolic deprivation or inﬂammatory
models (data not shown). We were unable to conﬁrm
the previously reported cellular pattern of Mincle pro-
tein expression in the mouse by immunohistochemistry
(IHC), largely because of the poor speciﬁcity of anti-
Mincle antibodies in mouse: conditions that gave least
staining in the Clec4e/ sections also lacked staining in
WT tissue (Supplementary Figure 1).
In rat, Mincle is expressed on CD163-positive
perivascular macrophages after permanent MCAO
In order to verify our observations that Mincle does not
have widespread expression in the brain, we examined
rat brain tissue after permanent MCAO.37 Throughout
the brain, in both infarct and non-ischemic tissue,
Mincleþ cells were always associated with the vascula-
ture. Monoclonal antibodies 4A9 (rat) and 16E3
(mouse) provided the same result (Figure 6). Mincle
was not present in cells positive for the pericyte
marker alpha-SMA (Figure 6(a) to (d)), with the astro-
cyte marker GFAP (Figure 6(a) and (c)) or with the
microglial marker Iba1 (Figure 6(c)). Mincleþcells
always appeared sandwiched between pericytes and
astrocytes (Figure 6(b)), and were positive for perivas-
cular macrophage marker CD16337 (Figure 6(d)).
Together these data conﬁrm that Mincle is not directly
regulating microglia or astrocyte responses to sterile
inﬂammation.
Discussion
The resistance of the Clec4e/ mice to ischemic brain
injury, but not to traumatic SCI, or peripheral (gut or
heart) ischemia strongly suggests a unique role
for Mincle in the context of cerebral ischemia.
Figure 6. Mincle immunofluorescence in the cortical contralateral (non-infarcted) region of rats subjected to permanent MCAO
shows presence of Mincle in the perivascular macrophages. (a) Mouse anti-Mincle antibody 16E3 shows Mincleþ cells do not
co-localize with pericytes (alpha-SMAþ) or astrocytes (GFAPþ), but with other cells located in the periphery of the blood vessels.
(b) Detail of the previous cell (* indicates position) showing a Mincleþ cell (red) located between pericytes (green) and astrocytes
(purple). (c) Mincleþ cells do not co-localize with microglia (Iba1þ). (d) Rat anti-Mincle antibody 4A9 staining shows co-localization
with CD163, a marker of perivascular macrophages. Scale bars: 20mm.
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Mincle’s major role is in the induction, rather than
propagation of ischemic inﬂammation, and the absence
of Mincle in the brain prevented the inﬁltration of per-
ipheral immune cells, reducing the activation of neutro-
phils and monocytes after transient focal cerebral
ischemia in mice. However, Mincle was not widely
expressed in brain. Its restricted pattern of expression
may indicate a role for Mincle in regulating cerebral
vasculature in response to injury, and thus help explain
the apparent diﬀerences in phenotype of the Mincle KO
mouse responding to brain MCAO or spinal cord
neurotrauma.
Further clariﬁcation of Mincle’s role in ischemic
stroke requires major improvements to the available
molecular toolkit for mouse. The use of the Mincle
KO mouse as a negative staining control revealed ser-
ious deﬁcits in most commonly used antibodies for
tissue staining in mouse. Yet, it is on the strength of
these antibodies that others have implicated Mincle in
changes to innate immunity after ischemic stroke,26
subarachnoid haemorrhage25 and traumatic brain
injury.38 We conﬁrmed by multiple molecular methods
(RNA and protein, in vitro and in vivo) that Mincle
was not present in mouse or rat neurons. Microglia are
radiation-resistant and thus retained in the recipient
animal in bone marrow chimeras,39 and we had
expected that these cells would be the most likely
source of Mincle-directed inﬂammation; however,
microglia isolated from sham-operated or tMCAO
brains one day after the injury did not express the
Clec4e mRNA, and the transcriptional proﬁle of
Mincle-deﬁcient microglia did not deviate from that
of isogenic controls, after sham surgery or ischemia.
There were no diﬀerences in microglia-derived TNF
production between WT and Clec4e/ animals after
tMCAO, and microglia from WT mice were unrespon-
sive to known Mincle-ligands.
The identity of the Mincle-positive cell associated
with the brain vasculature is intriguing. The classical
perivascular CD163þmacrophage is thought to be a
short-lived cell replenished from circulating CD14/
CD16 monocytes, and although we have not formally
demonstrated turnover of CD163þcells in our model,
prior lineage studies support the likelihood that most
perivascular macrophages are derived from bone
marrow recipients in our chimera experiments.40
However, a subset of perivascular-resident macro-
phages (the perivascular macrophage-like melanocyte,
PVM/M) are long-lived macrophages – less than 15%
turnover of these cells was reported three months post
bone marrow ablation and reconstitution.41 The
PVM/M shares a similar vascular distribution to our
pericyte-associated Mincleþcells, and are also interca-
lated with pericytes, extending processes to wrap
around the blood vessel. PVM/M has been
demonstrated as playing an important role in the qual-
ity of the blood–endothelial barrier in the inner ear.42
Further work is needed to conﬁrm that the previously
reported PVM/M expresses Mincle, that the
MincleþCD163þcells that we have reported here are
equally long-lived, or that these cells have a role in the
blood–brain barrier integrity in ischemic stroke; never-
theless, the longevity of this population is consistent
with the phenotype observed from our own bone
marrow chimera study, which would require the
MincleþCD163þperivascular cell to be resistant to
the bone-marrow ablation and therefore maintaining
the Clec4e genotype of the recipient mice.
The typical model for Mincle activation is as a nec-
rotic cell receptor, and prior studies suggest that is
active on CNS-resident cells.25,26,38 The inducible pres-
ence of Sap130 was also used as evidence for Mincle
activity, but this is somewhat puzzling because Sap130
is a constitutively expressed nuclear protein, made
available to immune receptors through cellular disrup-
tion via necrosis. Increased levels of Sap130 in whole
tissue lysates are therefore most consistent with recruit-
ment of additional cells to the lesion, perhaps due to
inﬂux of peripheral leukocytes.
Data presented here do not support the model of
Mincle as a necrotic cell receptor. Mincle is not
widely expressed on non-myeloid cells, and is not
expressed on microglia in the days following tMCAO,
so it is unlikely to be exerting its eﬀects directly on
neuronal survival or microglia activation. The lack of
Mincle-dependent phenotypes after SCI, and gut and
heart ischemia, challenges the widely held model of
Mincle as a peripheral myeloid receptor directing
inﬂammatory responses to areas of necrotic cell
damage. The Clec4e/ mouse phenotype does not
recapitulate that of other pattern recognition receptors
with roles in necrotic cell recognition. For example,
bone marrow chimera experiments using Tlr2 and/or
Tlr4 showed that recipient KO mice were equally sus-
ceptible to tMCAO as WT mice. Functional beneﬁt was
only observed in donors receiving KO bone marrow,
demonstrating that these receptors were most import-
ant in peripheral leukocyte activation.43 In contrast,
our own chimera studies demonstrated that the lack
of expression of Mincle on CNS-resident cells was pro-
tective regardless of the genotype of the donor marrow.
Loss of Mincle on peripheral immune cells had a rela-
tively small impact on the severity of MCAO. These
data indicate that Mincle predominantly acts on an
aspect speciﬁc to CNS architecture or function.
The signiﬁcant reduction in brain infarct size in
Clec4e/ animals suggests that blocking Mincle pro-
tects the cells in the penumbra region, that is, the brain
region where blood perfusion is low but suﬃcient to
maintain cell viability as a result of collateral blood
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vessel irrigation. Although we cannot fully exclude the
possibility of anatomical diﬀerences in the development
of the vasculature in Clec4e/ mice, the fact that
blockade of Mincle signaling with a Syk inhibitor
oﬀered a similar functional beneﬁt to genetic ablation
of Mincle strongly argues against this, pointing towards
functional diﬀerences in the response to the insult.
Exhaustive analysis of SCI, where the blood–CNS bar-
rier is disrupted by mechanical forces at the outset,
revealed no Mincle-dependant eﬀect. Certainly, many
features of the CNS response to an ischemic injury do
not apply to SCI, this includes the timing of recruit-
ment of inﬂammatory inﬁltrate,31 as well as diﬀerences
between the architecture and function of the blood–
brain barrier compared to the blood–spinal cord bar-
rier.44 In combination, these support our theory that
Mincle acts speciﬁcally in instances where the integrity
of the blood–CNS barrier is not directly compromised
by the initiating event.
The direct physical association between Mincleþ
perivascular macrophages and the adventitial plane of
alpha-SMAþ pericytes is evidence that these cells may
regulate brain microvasculature and/or breakdown of
the blood–brain barrier following an ischemic event.
The role of pericytes in the quality of blood ﬂow fol-
lowing reperfusion has been recently highlighted,45,46
where activation of pericytes leads to vascular constric-
tion and hyporeperfusion that exacerbates damage in
the penumbra region of a stroke lesion. We speculate
that Mincle expression by the pericyte-associated
macrophage has an instructive role between brain
injury and pericyte response.
An alternate and not mutually exclusive explanation
would be that Mincle has a role in directing inﬂamma-
tory cell recruitment across the blood–brain barrier,
which may have contributed to the observed reduction
in inﬂammatory inﬁltrate in the brains of Clec4e/mice
after stroke (Figure 2). This hypothesis is consistent with
observations that neutrophils transit across endothelial
barriers via pericyte processes,47 but it remains an open
question as to whether the Mincleþmacrophage asso-
ciated with the pericyte contributes to the traﬃc of
inﬂammatory monocytes, macrophages or neutrophils
across the blood–brain barrier.
Although our results leave many unanswered ques-
tions about the mechanism by which blocking Mincle
improves ischemic stroke outcomes, we demonstrate
that it does have a dramatic inﬂuence over the outcome
from brain ischemia and reperfusion injury, which
mainly emerges from Mincle’s presence in the brain
itself. The apparent speciﬁcity of Mincle in exacerbating
CNS injury and the likely availability of Mincle-
expressing cells in the vasculature of injured brains pro-
vide the ﬁeld with a new class of candidate in the search
for modiﬁable targets of inﬂammation during stroke.
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